OMAHA, NE - January 22, 2026 - PRESSADVANTAGE - Modern Vision Solutions has announced the publication of a new article, ...

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root ...

Interested parties may access the webcast here or at the events section of the Tarsus website. A replay will be available for a limited time at the same address. About TP-03TP-03 (lotilaner ophthalmic ...

Demodex blepharitis is a highly prevalent, yet often undiagnosed eyelid disease that impacts approximately 25 million eye care patients in the U.S. “We know that many patients struggle with eyelid ...

AJMC ®: Demodex blepharitis has a high estimated prevalence in the United States. However, few US studies of this disease exist. Why is this disease so understudied here? JACKSON: The main reason ...

Approximately 25 million eye care patients in the U.S. suffer from Demodex blepharitis, an eyelid disease characterized by inflammation, redness, and ocular irritation. 1-2 Demodex blepharitis is ...

AJMC®: Does the prevalence of Demodex blepharitis found by Trattler and colleagues 1 match what you see in clinical practice? BRUJIC: The prevalence of Demodex blepharitis is interesting. Prior to ...

Demodex blepharitis is a highly prevalent, yet often undiagnosed eyelid disease that impacts approximately 25 million eye care patients in the U.S. IRVINE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- ...

Add Yahoo as a preferred source to see more of our stories on Google. An image collage containing 2 images, Image 1 shows Illustration of Demodex folliculorum mite, Image 2 shows Close-up of a ...

IRVINE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize ...